AXGN

SEC source: 0001179110-19-002052 · edgar.xml · nonDerivative · entry 1

Gingrich Jon S. · CIK 0001711638 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,532

F1 · shares: This reflects the number of shares that became vested as of February 15, 2019 upon the attainment of certain performance criteria.

F1 · price: This reflects the number of shares that became vested as of February 15, 2019 upon the attainment of certain performance criteria.

SEC source: 0001179110-19-000862 · edgar.xml · derivative · entry 1

Sandberg Eric · CIK 0001764446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2029-01-21

F1 · derivative.exercise_date: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on January 21, 2023 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on January 21, 2021 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.

SEC source: 0001179110-18-014323 · edgar.xml · derivative · entry 2

Donovan Michael Patrick · CIK 0001653918 · VP Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,600

Underlying: Common Stock · 4,600 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock.

F3 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F3 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0001179110-18-014323 · edgar.xml · derivative · entry 1

Donovan Michael Patrick · CIK 0001653918 · VP Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,500

Underlying: Common Stock · 18,500 shares

Expires 2028-12-27

F1 · derivative.exercise_date: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on December 27, 2022 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.

SEC source: 0001179110-18-014324 · edgar.xml · derivative · entry 2

Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,600

Underlying: Common Stock · 4,600 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock.

F3 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F3 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0001179110-18-014324 · edgar.xml · derivative · entry 1

Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,500

Underlying: Common Stock · 18,500 shares

Expires 2028-12-27

F1 · derivative.exercise_date: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on December 27, 2022 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.

SEC source: 0001179110-18-014322 · edgar.xml · derivative · entry 2

Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,600

Underlying: Common Stock · 4,600 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock.

F3 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F3 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0001179110-18-014322 · edgar.xml · derivative · entry 1

Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,500

Underlying: Common Stock · 18,500 shares

Expires 2028-12-27

F1 · derivative.exercise_date: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on December 27, 2022 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.

SEC source: 0001179110-18-014321 · edgar.xml · derivative · entry 2

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,600

Underlying: Common Stock · 17,600 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock.

F3 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F3 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0001179110-18-014321 · edgar.xml · derivative · entry 1

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,700

Underlying: Common Stock · 59,700 shares

Expires 2028-12-27

F1 · derivative.exercise_date: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on December 27, 2022 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.

SEC source: 0001179110-18-014320 · edgar.xml · derivative · entry 2

MARIANI PETER J · CIK 0001222357 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,500

Underlying: Common Stock · 10,500 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock.

F3 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F3 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0001179110-18-014320 · edgar.xml · derivative · entry 1

MARIANI PETER J · CIK 0001222357 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,800

Underlying: Common Stock · 41,800 shares

Expires 2028-12-27

F1 · derivative.exercise_date: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on December 27, 2022 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.

SEC source: 0001179110-18-014319 · edgar.xml · derivative · entry 2

Scopelianos Angelo · CIK 0001751541 · VP Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,600

Underlying: Common Stock · 4,600 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock.

F3 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F3 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0001179110-18-014319 · edgar.xml · derivative · entry 1

Scopelianos Angelo · CIK 0001751541 · VP Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,900

Underlying: Common Stock · 32,900 shares

Expires 2028-12-27

F1 · derivative.exercise_date: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on December 27, 2022 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.

SEC source: 0001179110-18-014318 · edgar.xml · derivative · entry 2

MARTINEZ MARIA D. · CIK 0001633672 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,600

Underlying: Common Stock · 4,600 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock.

F3 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F3 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0001179110-18-014318 · edgar.xml · derivative · entry 1

MARTINEZ MARIA D. · CIK 0001633672 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,200

Underlying: Common Stock · 23,200 shares

Expires 2028-12-27

F1 · derivative.exercise_date: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on December 27, 2022 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.

SEC source: 0001179110-18-014317 · edgar.xml · derivative · entry 2

Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,600

Underlying: Common Stock · 4,600 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock.

F3 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F3 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0001179110-18-014317 · edgar.xml · derivative · entry 1

Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,200

Underlying: Common Stock · 23,200 shares

Expires 2028-12-27

F1 · derivative.exercise_date: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on December 27, 2022 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.

SEC source: 0001179110-18-014316 · edgar.xml · derivative · entry 2

DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,000

Underlying: Common Stock · 3,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock.

F3 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F3 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0001179110-18-014316 · edgar.xml · derivative · entry 1

DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,900

Underlying: Common Stock · 11,900 shares

Expires 2028-12-27

F1 · derivative.exercise_date: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on December 27, 2022 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.

SEC source: 0001179110-18-014315 · edgar.xml · derivative · entry 2

Hansen David K · CIK 0001362545 · VP Finance & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200

Underlying: Common Stock · 200 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock.

F3 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F3 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0001179110-18-014315 · edgar.xml · derivative · entry 1

Hansen David K · CIK 0001362545 · VP Finance & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 800

Underlying: Common Stock · 800 shares

Expires 2028-12-27

F1 · derivative.exercise_date: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on December 27, 2022 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.

SEC source: 0001179110-18-014217 · edgar.xml · derivative · entry 2

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,000 shares

Expires 2018-12-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-18-013429 · edgar.xml · nonDerivative · entry 1

Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,865

F1 · price: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan (the "Plan") adopted by the reporting person on September 7, 2018, as amended November 9, 2018. The sales resulted in the completion of the Plan so no more shares will be sold pursuant to the Plan.

F2 · price: The price reported is the actual sale price for all of these shares that were sold in multiple transactions. The reporting person undertakes to provide to AxoGen, Inc., any security holder of AxoGen, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the sale of the shares.

SEC source: 0001179110-18-013086 · edgar.xml · derivative · entry 3

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 70,000 shares

Expires 2018-12-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-18-013086 · edgar.xml · nonDerivative · entry 2

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 446,209

F1 · shares: This Form is being filed to report the exercise of a stock option for a total of 70,000 shares by means of a stock swap. A stock swap is a method of exercising a stock option in which the option holder pays the exercise price using shares of stock already owned. As a result of this stock swap, the Reporting Person, on a net basis, acquired ownership of an additional 63,239 shares of common stock.

SEC source: 0001179110-18-013086 · edgar.xml · nonDerivative · entry 1

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 452,970

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This Form is being filed to report the exercise of a stock option for a total of 70,000 shares by means of a stock swap. A stock swap is a method of exercising a stock option in which the option holder pays the exercise price using shares of stock already owned. As a result of this stock swap, the Reporting Person, on a net basis, acquired ownership of an additional 63,239 shares of common stock.

SEC source: 0001179110-18-014217 · edgar.xml · nonDerivative · entry 1

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 476,209

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-18-012899 · edgar.xml · nonDerivative · entry 1

Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,865

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.51. The reporting person undertakes to provide to AxoGen, Inc., any security holder of AxoGen, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001179110-18-012898 · edgar.xml · nonDerivative · entry 2

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 382,970

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.45 to $33.39. The reporting person undertakes to provide to AxoGen, Inc., any security holder of AxoGen, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001179110-18-012898 · edgar.xml · nonDerivative · entry 1

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 394,970

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.77 to $33.78. The reporting person undertakes to provide to AxoGen, Inc., any security holder of AxoGen, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001179110-18-012900 · edgar.xml · derivative · entry 5

DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 274 shares

Expires 2018-11-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-18-012900 · edgar.xml · derivative · entry 4

DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 35,000 shares

Expires 2018-12-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-18-012900 · edgar.xml · nonDerivative · entry 3

DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,410

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-18-012900 · edgar.xml · nonDerivative · entry 2

DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,136

F1 · shares: This Form is being filed to report the exercise of a stock option for a total of 35,000 shares by means of a stock swap. A stock swap is a method of exercising a stock option in which the option holder pays the exercise price using shares of stock already owned. As a result of this stock swap, the Reporting Person, on a net basis, acquired ownership of an additional 32,118 shares of common stock.

SEC source: 0001179110-18-012900 · edgar.xml · nonDerivative · entry 1

DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,018

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This Form is being filed to report the exercise of a stock option for a total of 35,000 shares by means of a stock swap. A stock swap is a method of exercising a stock option in which the option holder pays the exercise price using shares of stock already owned. As a result of this stock swap, the Reporting Person, on a net basis, acquired ownership of an additional 32,118 shares of common stock.

SEC source: 0001179110-18-012519 · edgar.xml · derivative · entry 1

MARTINEZ MARIA D. · CIK 0001633672 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2028-11-01

F1 · derivative.exercise_date: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on November 1, 2022 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on November 1, 2020 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.

SEC source: 0001179110-18-012518 · edgar.xml · derivative · entry 1

Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2028-11-01

F1 · derivative.exercise_date: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on November 1, 2022 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on November 1, 2020 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.

SEC source: 0001179110-18-012049 · edgar.xml · nonDerivative · entry 1

Gold Mark Stephen · CIK 0001531332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 344,761

F1 · balance_after: The shares of common stock for Dr. Gold include 212,761 shares held jointly by Dr. Gold and his wife and indirect ownership of 122,000 shares held by MJSK, Ltd., a decedent investment trust held by Dr. Gold's family. The transaction reflected on this Form 4 relates to the transfer of 20,000 indirect ownership shares held by Dr. Gold's spouse to MJKS, Ltd.

F1 · ownership.direct: The shares of common stock for Dr. Gold include 212,761 shares held jointly by Dr. Gold and his wife and indirect ownership of 122,000 shares held by MJSK, Ltd., a decedent investment trust held by Dr. Gold's family. The transaction reflected on this Form 4 relates to the transfer of 20,000 indirect ownership shares held by Dr. Gold's spouse to MJKS, Ltd.

SEC source: 0001179110-18-011633 · edgar.xml · derivative · entry 4

Grooms Jamie Mark · CIK 0001530935 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,000 shares

Expires 2018-10-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-18-011633 · edgar.xml · derivative · entry 3

Grooms Jamie Mark · CIK 0001530935 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 494 shares

Expires 2018-11-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-18-011633 · edgar.xml · nonDerivative · entry 2

Grooms Jamie Mark · CIK 0001530935 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,693

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: These shares of common stock include 372 shares held by the Jamie Grooms Trust, of which Mr. Grooms is the trustee.

SEC source: 0001179110-18-011633 · edgar.xml · nonDerivative · entry 1

Grooms Jamie Mark · CIK 0001530935 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,693

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: These shares of common stock include 372 shares held by the Jamie Grooms Trust, of which Mr. Grooms is the trustee.

SEC source: 0001182489-18-000359 · edgar.xml · derivative · entry 1

Scopelianos Angelo · CIK 0001751541 · VP Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2028-09-04

F1 · derivative.exercise_date: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on September 4, 2022 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on September 4, 2020 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.

SEC source: 0001179110-18-010631 · edgar.xml · nonDerivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,333

F1 · shares: The reporting person purchased these shares in her individual capacity in the open market and not through any directed share or other formal program.

F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $36.85 to $36.95. The reporting person undertakes to provide to AxoGen, Inc., any security holder of AxoGen, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

SEC source: 0001179110-18-010554 · edgar.xml · nonDerivative · entry 1

Gold Mark Stephen · CIK 0001531332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 344,761

F1 · balance_after: The shares of common stock for Dr. Gold include 212,761 shares held jointly by Dr. Gold and his wife, indirect ownership of 20,000 shares held by Dr. Gold's spouse and indirect ownership of 92,000 shares held by MJSK, Ltd., a decedent investment trust held by Dr. Gold's family. The transaction reflected on this Form 4 relates to the transfer by MJKS, Ltd. of an aggregate of 30,487 shares of common stock to Dr. Gold's adult children who do not share a household with Dr. Gold.

F1 · ownership.direct: The shares of common stock for Dr. Gold include 212,761 shares held jointly by Dr. Gold and his wife, indirect ownership of 20,000 shares held by Dr. Gold's spouse and indirect ownership of 92,000 shares held by MJSK, Ltd., a decedent investment trust held by Dr. Gold's family. The transaction reflected on this Form 4 relates to the transfer by MJKS, Ltd. of an aggregate of 30,487 shares of common stock to Dr. Gold's adult children who do not share a household with Dr. Gold.

SEC source: 0001179110-18-010454 · edgar.xml · derivative · entry 3

MCCARREY SHAWN F · CIK 0001195924 · SVP Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,000

Underlying: Common Stock · 55,000 shares

Expires 2020-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-18-010454 · edgar.xml · nonDerivative · entry 2

MCCARREY SHAWN F · CIK 0001195924 · SVP Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,921

F1 · shares: This Form is being filed to report the exercise of a stock option for a total of 55000 shares by means of a stock swap. A stock swap is a method of exercising a stock option in which the option holder pays the exercise price using shares of stock already owned. As a result of this stock swap, the Reporting Person, on a net basis, acquired ownership of an additional 49,864 shares of common stock.

SEC source: 0001179110-18-010454 · edgar.xml · nonDerivative · entry 1

MCCARREY SHAWN F · CIK 0001195924 · SVP Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,057

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This Form is being filed to report the exercise of a stock option for a total of 55000 shares by means of a stock swap. A stock swap is a method of exercising a stock option in which the option holder pays the exercise price using shares of stock already owned. As a result of this stock swap, the Reporting Person, on a net basis, acquired ownership of an additional 49,864 shares of common stock.

SEC source: 0001179110-18-010453 · edgar.xml · nonDerivative · entry 1

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 407,970

F1 · shares: This Form is being filed to report the delivery of shares of Common Stock of the Company for payment of tax liabilities that resulted from the exercise of a stock option reported on Form 4 for the reporting person filed on August 6, 2018. The fair market value of the Company's Common Stock on the date of exercise of such stock option was $39.25, and the amount of shares transferred to the Company on August 7, 2018 was based on the tax liability that accrued on the date of the exercise on August 2, 2018.